Gilmore Neil O'Neill

Executive

Chief Executive Officer

Editas Medicine, Inc.

Insider activity · 24 months0 buys8 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 1 saleJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 1 saleApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 1 saleJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 1 saleOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 1 saleJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (12 ops.)

€934k

Latest filing published 04 Sept 2026 for Editas Medicine, Inc., €13k.

Filing timeline

BuySale

Gilmore Neil O'Neill

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Gilmore Neil O'Neill: trading record in brief

Filings by Gilmore Neil O'Neill span 2 companies, the busiest being Editas Medicine, Inc. and Sarepta Therapeutics, Inc. Between 23 May 2019 and 3 September 2026, the trades on record add up to 23 filings.

On the market, this insider has only sold: 12 sales, €934k in total. Besides market trades, the filings include 10 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 3 sales.

Most recently, on 4 September 2026, the filings show an open-market sale worth €13k in Editas Medicine, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.